{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:35:26Z","timestamp":1772818526974,"version":"3.50.1"},"reference-count":36,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":4390,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2001,3]]},"abstract":"<jats:p>RG 12525 (2\u2010[[4\u2010[[2\u2010(1H\u2010tetrazole\u20105\u2010ylmethyl)phenyl]meth\u2010oxy]phenoxy]methyl] quinolone) is a novel peroxisome proliferator\u2010activated receptor gamma (PPAR\u2010\u03b3) agonist. In vitro microsomal inhibition assays indicated that RG 12525 is a potent inhibitor of CYP3A4, with a K<jats:sub>i<\/jats:sub> value of 0.5 \u03bcM. With the conservative assumption that the total plasma concentration of drug was available to metabolic enzymes following RG 12525 oral administration, marked inhibition of CYP3A4 was expected to substantially reduce the systemic clearance of compounds metabolized by this enzyme. The possibility also existed for inhibition of intestinal and hepatic CYP3A4 by RG 12525 to reduce \u201cfirst\u2010pass\u201d metabolism and increase absolute bioavailability of CYP3A4 substrates orally coadministered. Consequently, an in vivo drug\u2010drug interaction study was performed to evaluate the effects of orally administered RG 12525 on in vivo CYP3A4 activity in healthy male subjects. The pharmacokinetics of oral midazolam, a probe for intestinal and hepatic CYP3A activity, was not influenced by either the low (100 mg qd for 4 days) or high (600 mg qd for 4 days)RG 12525 dosing regimen despite the resulting total plasma concentrations of inhibitor that were well above in vitro K<jats:sub>i<\/jats:sub> values. The point estimates and 90% confidence intervals for the ratios of mean midazolam AUC for subjects administered 100 mg RG 12525 (110.6; 98.7\u2013124.1) and 600 mg RG 12525 (98.4; 84.4\u2013114.7) versus midazolam alone were within 80% to 125%. To explain these results, factors that could limit the accuracy of in vitro models in predicting metabolic drug interactions, mainly the high degree of RG 12525 protein binding (&gt; 99.9%), were considered. The lack of correlation between the in vitro inhibition of CYP3A4 by RG 12525 and the inconsequential effects of this compound on midazolam pharmacokinetics accentuate the need to recognize factors other than plasma drug concentrations and potency of in vitro enzyme inhibition when extrapolating in vitro data to predict in vivo drug\u2010drug interactions.<\/jats:p>","DOI":"10.1177\/00912700122010122","type":"journal-article","created":{"date-parts":[[2003,7,19]],"date-time":"2003-07-19T09:38:13Z","timestamp":1058607493000},"page":"305-316","source":"Crossref","is-referenced-by-count":8,"title":["Lack of Correlation between In Vitro Inhibition of CYP3A\u2010Mediated Metabolism by a PPAR\u2010\u03b3 Agonist and Its Effect on the Clinical Pharmacokinetics of Midazolam, an In Vivo Probe of CYP3A Activity"],"prefix":"10.1002","volume":"41","author":[{"given":"Jessica L.","family":"Fayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter N.","family":"Zannikos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey C.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajinder","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Kirkesseli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"issue":"12","key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/jama.1993.03500120051025","article-title":"Terfenadine\u2010ketoconazole interaction: pharmacokinetic and electrocardiographic consequences","volume":"269","author":"Honig PK","year":"1993","journal-title":"JAMA"},{"issue":"12","key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jama.1993.03500120088033","article-title":"Understanding consequences of concurrent therapies","volume":"269","author":"Peck CC","year":"1993","journal-title":"JAMA"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)79824-X"},{"issue":"5","key":"e_1_2_1_5_2","first-page":"543","article-title":"The influence of cisapride and clarithromycin on QT intervals in healthy volunteers","volume":"64","author":"Haarst AD","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01059791"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01059688"},{"key":"e_1_2_1_8_2","first-page":"420","article-title":"Prediction of hepatic extraction from in vitro measurement of intrinsic clearance","volume":"200","author":"Rane A","year":"1977","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_9_2","first-page":"513","volume-title":"Advances in Drug Metabolism in Man","author":"Boobis AR","year":"1995"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(94)90520-7"},{"issue":"3","key":"e_1_2_1_11_2","first-page":"387","article-title":"Prediction of pharmacokinetic alterations caused by drug\u2010drug interactions: metabolic interaction in the liver","volume":"50","author":"Ito K","year":"1998","journal-title":"Pharmacol Rev"},{"key":"e_1_2_1_12_2","first-page":"783","volume-title":"Advances in Drug Metabolism in Man","author":"Leeman TD","year":"1995"},{"issue":"12","key":"e_1_2_1_13_2","first-page":"1202","article-title":"Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics","volume":"26","author":"Lin JH","year":"1998","journal-title":"Drug Met Disp"},{"issue":"1","key":"e_1_2_1_14_2","first-page":"46","article-title":"The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data","volume":"283","author":"Obach RS","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(97)00239-6"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199835050-00003"},{"key":"e_1_2_1_17_2","first-page":"3","volume-title":"Metabolic Drug Interactions","author":"Thummel KE","year":"2000"},{"key":"e_1_2_1_18_2","first-page":"114","article-title":"In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog, and man","volume":"59","author":"Baarnheilm C","year":"1986","journal-title":"Acta Pharmacol et Toxicol"},{"issue":"12","key":"e_1_2_1_19_2","first-page":"1359","article-title":"Nonspecific binding to microsomes: impact on scale\u2010up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol","volume":"25","author":"Obach RS","year":"1997","journal-title":"Drug Met Disp"},{"issue":"10","key":"e_1_2_1_20_2","first-page":"1047","article-title":"The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro\u2010in vivo correlations","volume":"24","author":"Obach RS","year":"1996","journal-title":"Drug Met Disp"},{"issue":"11","key":"e_1_2_1_21_2","first-page":"1350","article-title":"Prediction of human clearance of twenty\u2010nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half\u2010life approach and non\u2010specific binding to microsomes","volume":"27","author":"Obach RS","year":"1999","journal-title":"Drug Met Disp"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70009-3"},{"issue":"1","key":"e_1_2_1_23_2","first-page":"1","article-title":"Effect of common organic solvents on in vitro cytochrome CYP\u2010mediated metabolic activities in human liver microsomes","volume":"26","author":"Chauret N","year":"1998","journal-title":"Drug Met Disp"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)52451-6"},{"issue":"9","key":"e_1_2_1_25_2","first-page":"948","article-title":"Catalytic role of cytochrome CYP2B6 in the N\u2010demethylation of S\u2010mephenytoin","volume":"24","author":"Heyn H","year":"1996","journal-title":"Drug Met Disp"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(87)90006-6"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018906614320"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1054-3589(08)60202-1"},{"key":"e_1_2_1_29_2","first-page":"115","volume-title":"Metabolic Drug Interactions","author":"Wrighton SA","year":"2000"},{"issue":"2","key":"e_1_2_1_30_2","first-page":"161","article-title":"Prediction of pharmacokinetic drug\/drug interactions from in vitro data: interactions of the nonsteriodal anti\u2010inflammatory drug lornoxicam with oral anticoagulants","volume":"28","author":"Kohl C","year":"2000","journal-title":"Drug Met Disp"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1996.tb04251.x"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1994.tb04735.x"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199712000-00013"},{"issue":"5","key":"e_1_2_1_34_2","first-page":"596","article-title":"Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole","volume":"27","author":"Gibbs MA","year":"1999","journal-title":"Drug Met Disp"},{"key":"e_1_2_1_35_2","first-page":"29","volume-title":"Metabolic Drug Interactions","author":"Ring BJ","year":"2000"},{"issue":"3","key":"e_1_2_1_36_2","first-page":"395","article-title":"Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver","volume":"27","author":"Yamano K","year":"1999","journal-title":"Drug Met Disp"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1054-3589(08)60208-2"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F00912700122010122","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/00912700122010122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T14:42:07Z","timestamp":1700404927000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/00912700122010122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,3]]}},"alternative-id":["10.1177\/00912700122010122"],"URL":"https:\/\/doi.org\/10.1177\/00912700122010122","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,3]]}}}